23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Are you also related to Charlemagne, described as 'one of the most important people in history'? Well, according to scientists, it's not difficult to find out.

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Advances in DNA technology in the past three decades led Everett police to a Las Vegas man who was Maryann Daniels' neighbor when she was killed in 1989.

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.